Document Detail

Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia.
MedLine Citation:
PMID:  15338855     Owner:  NLM     Status:  MEDLINE    
STUDY OBJECTIVE: To evaluate the cost of a pharmacist-directed intervention that prompts physicians to treat hypercholesterolemia more aggressively in patients with coronary heart disease (CHD). METHODS: Health care resource use and CHD outcomes were evaluated for 612 patients with CHD followed for 2 years after an index hospitalization for an ischemic event. After discharge, the physicians of 309 patients who had been admitted from January 1--March 31, 1999, were contacted by telephone and mail concerning lipid profiles and statin therapy. These patients were the intervention group. Controls were 303 patients admitted from October 1--December 31, 1998; their physicians were not contacted. Costs of the physician-prompting intervention, clinic visits, laboratory tests, statin drugs, and CHD outcomes were compared between these two patient groups. RESULTS: The number of clinic visits, laboratory tests, and statins prescribed was significantly greater for the intervention group versus the controls. A significantly higher percentage of patients in the intervention group (55%) than in the control group (18%) achieved their National Cholesterol Education Program target low-density lipoprotein cholesterol level and had significantly better CHD outcomes. The cost of the physician-prompting intervention (pharmacist salaries, postage, telephone calls) was $102,941. For patients in the intervention and control groups, respectively, the cost of statin therapy was $352,365 and $200,087, the cost of clinic visits and laboratory tests $48,097 and $27,367, and the cost of coronary heart disease outcomes, such as myocardial infarction, coronary artery bypass graft, percutaneous transluminal and coronary angioplasty, $1,073,495 and $1,741,220. The total cost was $1,576,898 and $1,968,674, respectively, for patients in the intervention and control groups. Net savings was $1394/patient over the 2-year period. CONCLUSION: A relatively simple physician-prompting intervention involving patients with CHD significantly improved the use of lipid testing and statin therapy. Improved use of statins was associated with better CHD outcomes. As a result, the physician-prompting intervention was associated with cost savings. This intervention should be implemented for patients with CHD discharged after hospitalization for an ischemic event.
Daniel E Hilleman; Michele A Faulkner; Michael S Monaghan
Related Documents :
9108785 - The role of triglyceride-rich lipoprotein families in the progression of atheroscleroti...
11879715 - Simvastatin retards progression of retinopathy in diabetic patients with hypercholester...
11849465 - Mycophenolate mofetil treatment for primary glomerular diseases.
12065175 - Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausa...
11112935 - Valpromide increases amplitude of heart rate circadian rhythm in remitted bipolar and u...
11159875 - Prucalopride accelerates gastrointestinal and colonic transit in patients with constipa...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  24     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-09-01     Completed Date:  2004-10-26     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1077-83     Citation Subset:  IM    
School of Pharmacy and Health Professions, Creighton University Medical Center, Omaha, Nebraska 68178, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Coronary Disease / complications,  economics
Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics,  therapeutic use*
Hypercholesterolemia / complications,  drug therapy*,  economics
Middle Aged
Pharmaceutical Services / economics*
Treatment Outcome
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?
Next Document:  Candida kefyr, an uncommon but emerging fungal pathogen: report of two cases.